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Abstract
Invasive aspergillosis (IA) is a major threat to the successful outcome of hematopoietic stem cell transplantation (HSCT),
although individual risk varies considerably. Recent evidence has established a pivotal role for a danger sensing mechanism
implicating the S100B/receptor for advanced glycation end products (RAGE) axis in antifungal immunity. The association of
selected genetic variants in the S100B/RAGE axis with susceptibility to IA was investigated in 223 consecutive patients
undergoing HSCT. Furthermore, studies addressing the functional consequences of these variants were performed.
Susceptibility to IA was significantly associated with two distinct polymorphisms in RAGE (-374T/A) and S100B (+427C/T)
genes, the relative contribution of each depended on their presence in both transplantation counterparts [patient SNPRAGE,
adjusted hazard ratio (HR), 1.97; P= 0.042 and donor SNPRAGE, HR, 2.03; P= 0.047] or in donors (SNPS100B, HR, 3.15; P= 7.8e-
4)
only, respectively. Functional assays demonstrated a gain-of-function phenotype of both variants, as shown by the
enhanced expression of inflammatory cytokines in RAGE polymorphic cells and increased S100B secretion in vitro and in vivo
in the presence of the S100B polymorphism. These findings point to a relevant role of the danger sensing signaling in
human antifungal immunity and highlight a possible contribution of a genetically-determined hyperfunction of the S100B/
RAGE axis to susceptibility to IA in the HSCT setting.
Citation: Cunha C, Giovannini G, Pierini A, Bell AS, Sorci G, et al. (2011) Genetically-Determined Hyperfunction of the S100B/RAGE Axis Is a Risk Factor for
Aspergillosis in Stem Cell Transplant Recipients. PLoS ONE 6(11): e27962. doi:10.1371/journal.pone.0027962
Editor: Gustavo Henrique Goldman, Universidade de Sao Paulo, Brazil
Received July 26, 2011; Accepted October 28, 2011; Published November 17, 2011
Copyright:  2011 Cunha et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Specific Targeted Research Projects ‘‘ALLFUN’’ (FP7-HEALTH-2010-single-stage, contract number 260338) and
‘‘SYBARIS’’ (FP7-HEALTH-2009-single-stage contract number 037899), by the Fondazione per la Ricerca sulla Fibrosi Cistica (FFC#21/2010) and by the Fondazione
Cassa di Risparmio di Perugia (2009.020.0021). CC and AC were financially supported by fellowships from Fundac¸a˜o para a Cieˆncia e Tecnologia, Portugal
(contracts SFRH/BD/65962/2009 and SFRH/BPD/46292/2008, respectively). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: aacarvalho2008@gmail.com
Introduction
Invasive aspergillosis (IA) is a disease typically affecting high-risk
patients such as that undergoing allogeneic hematopoietic stem
cell transplantation (HSCT). Despite antifungal therapy, IA
remains a leading cause of death among transplant recipients
with a 1-year mortality reaching 75% [1–2]. Although displaying
apparently similar ‘‘immunocompromised’’ phenotypes, not all
HSCT recipients eventually develop disease, suggesting that
genetically-determined immune defects may also play a role in
defining susceptibility to IA [3]. In effect, single nucleotide
polymorphisms (SNPs) in TLR4 and DECTIN1 have been recently
proposed as strong predictive factors for incidence of IA [4–5] or
fungal colonization [6] following HSCT.
Pathogen recognition through pathogen-associated molecular
patterns (PAMPs) and from reaction to tissue damage-associated
molecular patterns (DAMPs) is critical in establishing inflamma-
tion and resistance to infection [7–8]. However, unrestrained
inflammation may also hamper the normal eradication of infection
[9]. DAMPs such as high mobility group box 1 (HMGB1) and
S100 proteins mediate inflammatory reactions through interaction
with the multiligand receptor for advanced glycation end products
(RAGE) [10–13]. Indeed, ligand-RAGE engagement has been
highlighted as an amplifying mechanism of inflammation in
immune/inflammatory diseases through a positive feedback loop
between ligand availability and receptor expression [14].
Recently, a role for DAMP signaling has also been demon-
strated in antifungal immunity [15]. S100B, a Ca2
+-binding
protein of the EF-hand type [16], was found to be critical for the
integration of pathogen- and danger-sensing pathways to restrain
inflammation in Aspergillus fumigatus infection [15]. However, when
in excess, it adversely affected infection’s outcome via the
inflammatory RAGE pathway [15]. Based on this experimental
evidence, polymorphisms within regulatory elements or ligand
binding sites may potentially orchestrate RAGE’s functional
activity as well as ligand accumulation, so that certain individuals
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may be predisposed to heightened inflammatory responses and
failure to control infections. Indeed, the nonsynonymous G82S
polymorphism has been found to promote glycosylation and
increased ligand affinity, upregulating intracellular signaling
pathways linked with modulation of proinflammatory genes [17–
18]. A gain-of-function effect was also demonstrated for the
-374T/A polymorphism, resulting in enhanced transcriptional
activity by impairing the binding of regulatory elements to the
gene promoter [19–20]. Elevated serum concentrations of S100B,
associated with certain immuno-mediated diseases [16], have been
linked with genetic variants in the S100B gene [21].
We investigated the association of functional polymorphisms in
the S100B/RAGE axis with susceptibility to IA in 223 consecutive
HSCT recipients. Mechanistically, functional studies are presented
supporting a genetically-determined hyperfunction of the S100B/
RAGE axis as an additional risk factor for the development of IA
in HSCT patients.
Methods
Patients
To assess the role of the DAMP system in aspergillosis, we
analyzed a cohort of 223 consecutive patients with hematological
malignancies who underwent allogeneic T-cell-depleted HSCT in
Perugia between 2003 and 2010, and respective donors. Patient
characteristics included patient age and gender, relation donor-
patient gender, underlying disease and stage, transplant matching,
CMV serology of donors and patients, conditioning regimen,
graft-versus-host disease (GVHD) and antifungal prophylaxis
(Table 1). Grafts consisted of immunoselected CD34+ peripheral
blood cells in all cases and transplantation procedures were
performed as described [22]. No GVHD prophylaxis or granulo-
cyte colony-stimulating factor was administered after transplanta-
tion. Steroid therapy was performed in patients with diagnosed
GVHD. Study approval was provided by the local ethics
committee (Umbria Regional Hospital Ethics Committee, CEAS
Umbria) and informed written consent was obtained from all
participants in accordance with the Declaration of Helsinki.
Antifungal prophylaxis included liposomal amphotericin-B (1 mg/
kg daily) in high-risk patients (n= 195; 87.4%) and fluconazole
(400 mg daily) in standard risk patients (n=28; 12.6%) from day25
until neutropenia ended. Criteria defining standard and high risk for
IA were applied as described [23]. Surveillance cultures from stool,
urine, nasal and oral washes were performed at the time of
transplantation. Additionally, blood, sputum, bronchoalveolar lavag-
es (BAL), serum galactomannan (Platelia Aspergillus EIA, Bio-Rad,
Hercules, CA) and cultures of samples were analyzed when clinical
symptoms of infection appeared. Probable/proven fungal infection
was defined according to the revised standard criteria from the
European Organization for Research and Treatment of Cancer/
Mycology Study Group (EORTC/MSG) [24].
DNA isolation and SNP genotyping
Genomic DNA from patients and donors was isolated from
whole blood before transplantation using the QIAamp DNA
Blood Mini kit (Qiagen, Milan, Italy) according to manufacturer’s
instructions. The RAGE (rs2070600, 2374T/A and rs1800624,
G82S) and S100B (rs9722, +427C/T) polymorphisms were
selected from a literature review and public databases based on
three selection criteria: i) published evidence of association with
human diseases [18–21], ii) localization to the promoter,
untranslated (UTR) or coding sequence, and (iii) minor allele
frequencies higher than 5% in the Caucasian population.
Genotyping was performed using bi-directional PCR amplification
of specific alleles (Bi-PASA) as previously described [25], or using
allele-specific PCR. Primer sequences are described in Table S1.
Genotyping was validated by direct sequencing of at least 30
randomly selected DNA samples from either patients or donors for
each polymorphism. Genotyping sets comprised randomly selected
replicates of previously typed samples and two negative controls
(water). Concordant genotyping was obtained for $99% assays.
In silico miRNA prediction
The +427C/T polymorphism within the 39-UTR region of the
S100B gene was analyzed in order to predict and compare
alteration of potential microRNA targeting sites. Analysis was
performed using the TargetScan version 4.0 (http://www.
targetscan.org/) and microSNiPer (http://cbdb.nimh.nih.gov/
microsniper) public databases. A minimum ‘‘seed’’ length of 7-
mer was specified as minimum cut-off score.
Reagents
Recombinant bovine S100B, 96% identical to human S100B,
was expressed and purified as reported [26–27]. Purified S100B
was passed through an END–X B15 Endotoxin Affinity Resin
Table 1. Patient, disease and transplantation characteristics
(N = 192).
Characteristic
No IA
(n =151)
IA*
(n =41) P{
Age at transplantation, years [median
(range)]
38 (6–68) 39 (14–66) 0.65
Sex, no. (%) male 73 (48) 18 (44) 0.65
Sex of donor/patient pair
Female/male 37 (25) 7 (17)
Others 114 (75) 34 (83) 0.31
HLA matching, no. (%)
HLA-identical sibling 64 (42) 11 (27)
One HLA haplotype-mismatched family
member
87 (58) 30 (73) 0.05
Underlying disease, no. (%)
Acute leukemia 105 (69) 23 (56)
Lymphoma/myeloma 36 (24) 13 (32)
Chronic leukemia 10 (7) 5 (12) 0.31
Advanced disease stage, no. (%) 98 (65) 30 (73) 0.29
Conditioning regimen, no. (%)
With TBI 108 (72) 34 (83)
Without TBI 43 (28) 7 (17) 0.16
CMV serology of donor and recipient,
no. (%)
CMV-/CMV- 15 (10) 4 (10)
CMV-/CMV+, CMV+/CMV- or CMV+/CMV+ 136 (90) 37 (90) 0.94
GVHD, grade II to IV, no. (%) 5 (3) 5 (12) 0.04
Antifungal prophylaxis, no (%)
Liposomal amphotericin-B 127 (84) 40 (98)
Fluconazole 23 (16) 1 (2) 0.03
IA – invasive aspergillosis; HLA – human leukocyte antigen; TBI – total body
irradiation; CMV – cytomegalovirus; GVHD – graft-versus-host-disease.
*Patients diagnosed with possible aspergillosis (n = 31) were excluded from the
study.
{P values are from Gray’s test using cumulative incidence analysis.
doi:10.1371/journal.pone.0027962.t001
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column (Associates of Cape Cod, Inc., East Falmouth, MA) to
remove contaminating bacterial endotoxin. Endotoxin levels
(,1.0 EU/mL) were verified by a standard assay using a Limulus
amoebocyte lysate reagent test kit (Associates of Cape Cod, Inc.).
S100B concentration was calculated using the molecular weight of
the S100B dimer (21 kDa). Recombinant HMGB1 was a kind gift
from Heikki Rauvala (University of Helsinki, Helsinki, Finland).
Cell preparation, cultures and treatments
In order to assess the functional consequences of the genetic
variants in the S100B/RAGE axis, we resorted to human cells from
individuals bearing distinct genotypes. Upon written informed
consent, human peripheral blood mononuclear cells (PBMCs) from
whole blood of healthy volunteers were isolated using sterile-filtered
HistopaqueH-1077 (Sigma-Aldrich, St. Louis, MO) according to
manufacturer’s instructions. Cells (2.56106 cells/mL) were stimu-
lated with S100B (4 nM and 4 mM), HMGB1 (300 nM), Zymosan
(Zym, 10 mg/mL) or inactivated A. fumigatus conidia (1:1 ratio) for
2 hours before RNA extraction or 12 hours before supernatant
collection and cell lysis. The nanomolar versus micromolar
concentrations of S100B were selected based on their antagonizing
effects in inflammation, as previously described [15]. For each assay,
cells from either wild-type (n= 10) or polymorphic (n= 10)
individuals for the RAGE and S100B variants were used. Cells from
the same individuals were used across conditions in each assay.
BAL collection
To assess potential genetically-determined differences in S100B
levels in IA patients, we measured S100B concentrations in BAL
samples from HSCT recipients. Sample collection was performed as
per EORTC/MSG criteria [24] in line with the respective institu-
tional procedures and standardized according to the guidelines
proposed by the European Respiratory Society to measure acellular
components [28]. All patients were non-smokers without any other
relevant associated disease (e.g. asthma) and were undergoing identi-
cal drug regimens. All BAL samples were obtained by the instillation
of 150 ml of fluid and comparable recovery rate, therefore preventing
errors associated with dilution and stored at -80uC until use.
Real–time RT-PCR analysis
Real–time RT–PCR was performed using the iCycler iQdetec-
tion system (Bio–Rad) and SYBR Green chemistry (Finnzymes
Oy, Espoo, Finland). Total RNA was extracted using RNeasy
Mini Kit (QIAGEN) and was reverse transcribed with Sensiscript
Reverse Transcriptase (QIAGEN) according to manufacturer’s
instructions. PCR primers are described in Table S1. Amplifica-
tion efficiencies were validated and normalized against b-actin
(ACTB). The thermal profile for real-time RT-PCR was 95uC for
3 min, followed by 40 cycles of denaturation for 30 s at 95uC and
an annealing/extension step of 30 sec at 60uC. Each data point
was examined for integrity by analysis of the amplification plot.
mRNA–normalized data were expressed as relative mRNA
expression in stimulated cells compared to that of wild-type
untreated cells.
ELISA assays
Supernatants from PBMC cultures were collected after
stimulation and BAL samples from patients with IA were obtained
before initiation of treatment. ELISA for S100B was performed as
follows: 50 ml of sample were incubated overnight on a microtiter
plate previously coated with a monoclonal mouse anti-S100B
antibody (Sigma-Aldrich). A rabbit anti-S100B antibody (EPOS)
conjugated with peroxidase (Dako, Copenhagen, Denmark) was
then added for 1 hour before the color reaction with SIGMA-
FASTTM OPD peroxidase substrate (Sigma-Aldrich) was measured
at 492 nm. The standard S100B curve ranged from 0.2 to 40 ng/
mL.
Western blotting
Blots of cell lysates were incubated with a goat polyclonal anti-
RAGE IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
followed by addition of horseradish peroxidase-conjugated anti-
goat IgG secondary antibody (Cell Signaling Technology,
Danvers, MA). Blots were developed with the Enhanced
Chemiluminescence detection kit (Amersham Pharmacia Biotech,
Milan, Italy). Control experiments included staining without the
primary antibody.
Statistical analysis
Consistency of genotype frequencies with the Hardy–Weinberg
equilibrium was tested using a x2 test on a contingency table of
observed vs. predicted genotype frequencies (P.0.05). Probability
of IA was determined using the Gray’s test and analyzed using the
cumulative incidence method. Cumulative incidences were com-
puted with the cmprsk package for R 2.10.1 software [29], with the
competing events for IA being relapse and death. Overall survival
was defined as the time from first day of treatment to death from any
cause and was obtained by the Kaplan-Meier method and
compared using the log-rank test. Clinical co-variables depicted in
Table 1, as well as donor and patient genotype, were tested in
univariate analyses. GVHD was considered in the univariate
analysis as a time-dependent covariate for IA. Variables with a
P value#0.15, namely transplant matching, GVHD and antifungal
prophylaxis, were included in the multivariate model. Multivariate
analysis was performed for each polymorphism separately using the
subdistribution regression model of Fine and Gray with the cmprsk
package for R 2.10.1 software [30]. Functional data were analyzed
by GraphPad Prism 4.03 program (GraphPad Software, San Diego,
CA). Unpaired Student’s t-test with Bonferroni’s adjustment and
2-tailed Mann-Whitney rank-sum test were used to determine
statistical significance (P,0.05).
Results
Polymorphisms in the S100B/RAGE axis and risk of IA in
HSCT recipients
The G82S polymorphism in RAGE was eventually excluded
from the analyses given it displayed a minor allele frequency lower
than 5% in our patient cohort (data not shown). Genotype
frequencies of the remaining RAGE and S100B polymorphisms
were comparable among patients, donors and healthy individuals
(Table 2) and were not significantly different with regard to the
underlying hematological disease (Table S2) or antifungal
prophylaxis (Table S3). Among the 223 patients enrolled in our
study, 41 (18%) developed proven/probable IA within a median
time of 97 days (range, 1–390 days) following HSCT. Thirty-four
(15%) patients with diagnosis of possible infection or with history
of pretransplantation disease were excluded from further analyses.
Ninety-five (43%) patients were long-term survivors following
transplantation; median follow-up time among surviving patients
was 45 months (range, 5 to 100) and among those who died was 7
months (range, 1 to 57). No statistically significant influence of
RAGE or S100B polymorphisms on patient survival was found
(data not shown).
To estimate the risk of IA according to patient or donor
genotypes, we determined cumulative incidences of IA among
transplant recipients at the date of the last documented case. RAGE
S100B/RAGE and Aspergillosis in HSCT
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27962
-374T/A polymorphism increased susceptibility to IA when present
in either patients [12.7% WTRAGE (wild-type, TT genotype) vs.
28.6% SNPRAGE (TA+AA genotypes); P=0.008] or donors (15.6%
WTRAGE vs. 27.7% SNPRAGE; P=0.029) (Figure 1A). In contrast,
S100B +427C/T polymorphism predisposed to IA when present in
donors [17.2% WTS100B (wild-type, CC genotype) vs. 42.9%
SNPS100B (CT+TT genotypes); P=4e24], but not in patients
(22.7% WTS100B vs. 18.9% SNPS100B; P=0.70) (Figure 1B).
In the multivariate analysis, all genetic associations remained
significant, as well as the clinical co-variables HLA-haplotype
Table 2. Genotype distributions of RAGE and S100B polymorphisms in donors and recipients of stem cell transplants and healthy
controls.
Genotype Donor (n=223) Recipient (n =223) Healthy controls (n =468) P*
WTRAGE 108 (48.4%) 97 (43.5%) 215 (45.9%)
SNPRAGE 115 (51.6%) 126 (56.5%) 253 (54.1%) 0.58
WTS100B 188 (84.3%) 182 (81.6%) 390 (83..3%)
SNPS100B 35 (15.7%) 41 (18.4%) 78 (16.7%) 0.74
WT – wild-type; SNP – single nucleotide polymorphism. WTRAGE – TT genotype; SNPRAGE – TA + AA genotypes; WTS100B – CC genotype; SNPS100B – CT + TT genotypes.
*P values are calculated with the Freeman-Halton extension of the Fisher’s exact test for a two-rows by three-columns contingency table.
doi:10.1371/journal.pone.0027962.t002
Figure 1. Polymorphisms in the S100B/RAGE axis and risk of IA in HSCT recipients. (A) Cumulative incidence of IA according to RAGE
-374T/A genotype (WTRAGE, TT; SNPRAGE, TA+AA). (B) Cumulative incidence of IA according to S100B +427C/T genotype (CC, WTS100B; CT+TT, SNPS100B).
From left to right, patients (R) and donors (D).
doi:10.1371/journal.pone.0027962.g001
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mismatching and GVHD (Table 3). SNPRAGE genotypes in
patients and donors independently resulted in a 2-fold increased
risk of IA after HSCT, when compared to their wild-type
counterparts. Instead, donor SNPS100B genotype promoted a 3-
fold increased risk of IA compared to WTS100B donors. It is also
interesting to note that the effects of these polymorphisms were
restricted to IA. In fact, no other clinical outcomes assessed in our
cohort such as relapse, transplant-related mortality or GVHD, as
well as infectious outcomes, specifically cytomegalovirus (CMV)
disease, were influenced by RAGE or S100B polymorphisms
(Figure S1).
Functional consequences of RAGE and S100B
polymorphisms
To determine whether RAGE expression was altered by the
-374T/A polymorphism, we analyzed WTRAGE (TT genotype) and
SNPRAGE (AA genotype) PBMCs isolated from healthy individuals.
Cells were either left untreated or stimulated with A. fumigatus
conidia, S100B or HMGB1. We found that PBMCs carrying the
SNPRAGE genotype displayed an increased expression of RAGE
compared to WTRAGE cells (Figure 2A). Stimulation with A.
fumigatus conidia, S100B (particularly at the micromolar dose) and
HMGB1 further amplified this effect (Figure 2B). The fact that
RAGE expression was modulated in cells pulsed with the fungus
confirms the important role of the RAGE pathway in antifungal
immunity [15].
We also investigated cytokine stimulation in treated WTRAGE
and SNPRAGE PBMCs (Figure 2C). Cells isolated from SNPRAGE
individuals showed increased expression of IL17A, and to a lesser
extent, of IFNG, as well as decreased expression of IL4, in response
to the micromolar concentration of S100B and to HMGB1
compared to WTRAGE cells. No significant differences between
genotypes were observed for IL10, IL6 or TNF (Figure S2).
Stimulation with A. fumigatus conidia did not trigger significant
IL17A expression, a finding consistent with the fact that human
anti-Aspergillus immunity relies more on Th1 than Th17 type of
response [5,31]. Confirming the human in vitro data, a similar
inflammatory pattern of cytokine expression was also observed in
the lungs of mice infected with A. fumigatus and treated with the
RAGE ligands (Figure S3; Methods S1).
To dissect possible molecular mechanisms underlying the effect
of the +427C/T polymorphism in S100B and given its location in
the gene, we examined possible consequences on the binding of
regulatory miRNAs. As shown in Figure 3A, in silico analyses
identified alterations in binding sites for miR-593 and miR-3675-
3p in the 39-untranslated sequence of S100B that depended on the
presence of the polymorphism. Therefore, to investigate whether
S100B expression and secretion was modulated by the +427C/T
polymorphism, we analyzed PBMCs isolated from WTS100B (CC
genotype) and SNPS100B (CT genotype) individuals. SNPS100B
PBMCs displayed increased levels of S100B mRNA even in basal
conditions when compared with WTS100B cells (Figures 3B).
Stimulation of cells with A. fumigatus conidia or Zym, used as
positive control (13), enhanced S100B gene induction as compared
to the untreated conditions. Similar results were obtained
measuring S100B levels in PBMC supernatants where S100B
was found to be secreted in higher amounts by polymorphic
PBMCs compared to WTS100B cells (Figure 3C). Furthermore, we
collected BAL samples from 26 wild-type patients for S100B
diagnosed with proven/probable IA, 13 of which had S100B
polymorphic donors and the remaining, wild-type donors. As seen
in Figure 4, the median concentration of S100B in BAL samples
was significantly higher in patients with IA with a polymorphic
donor for S100B than in those with a wild-type donor (3218 vs.
203 pg/mL; interquartile ranges, 1940–9187 and 10–1632 pg/
mL, respectively; P=0.016). Of interest, the levels of sRAGE in
BAL samples were not significantly different among patients with
distinct patient/donor RAGE genotypes (Figure S4; Methods S1).
Discussion
The immune system has evolved to respond not only to
pathogens but also to signals released from damaged and dying
cells. The DAMP/RAGE axis is central in danger signaling
responses, promoting inflammation and alerting the immune
system to the presence of damaging insults. However, sustained
activation of danger signaling has been widely implicated in the
pathogenesis of multiple diseases with an inflammatory/immune
component [14]. Accordingly, several polymorphisms in genes
involved in the DAMP/RAGE axis have also been described to
influence susceptibility to a number of inflammatory conditions
[21,32–36].
In this study, we demonstrate that genetic variants in RAGE and
S100B genes increase susceptibility to IA in HSCT recipients, a
finding consistent with recent evidence pointing to a previously
unsuspected role of S100B/RAGE-mediated mechanisms in host
defense against A. fumigatus infection [15]. The specific effect of
each genetic variant was found to depend on either patient or
donor (RAGE -374T/A) or exclusively on donor (S100B +427C/T)
genetic make-up. This suggests that impairment of RAGE’s
activity in either patients or donors predisposes to IA, whereas the
contribution of S100B-dependent mechanisms relies on its
function in the hematopoietic compartment. The fact that these
associations were restricted to IA highlights how A. fumigatus, more
than CMV, is endowed with the ability to trigger danger sensing
signaling in the lung, known to express high levels of RAGE under
normal conditions [37].
The RAGE -374T/A polymorphism has been demonstrated to
enhance transcriptional activity by restricting the binding of
repressor elements to the gene promoter [19–20]. We found
increased expression of RAGE in human polymorphic mononu-
clear cells. RAGE expression was further enhanced upon
engagement by its cognate ligands, a finding consistent with the
ability of agonists of membrane RAGE to up-regulate its own
Table 3. Multivariate analysis of the association of RAGE
-374T/A and S100B +427C/T polymorphisms with risk of IA
following HSCT.
Risk factors* Adjusted HR 95% CI P
RAGE -374T/A
R SNPRAGE 2.03 1.01–4.10 0.047
D SNPRAGE 1.97 1.02–3.79 0.042
HLA mismatching 2.16 1.08–4.31 0.029
GVHD 3.21 1.26–8.20 0.015
S100B +427C/T
D SNPS100B 3.15 1.61–6.15 7.8e
4
HLA mismatching 1.99 1.03–3.87 0.042
GVHD 2.80 1.00–8.48 0.050
R: recipient; D: donor; HR: hazard ratio; CI: confidence interval; HLA: human
leukocyte antigen; GVHD: graft-versus-host-disease; SNPRAGE, TA + AA
genotypes; SNPS100B, CT + TT genotypes.
*For the genetic factors, R WTRAGE, D WTRAGE and D WTS100B genotypes are the
referent categories, respectively.
doi:10.1371/journal.pone.0027962.t003
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expression and activate a proinflammatory signaling cascade [20].
Indeed, RAGE activation associated with enhanced expression of
proinflammatory cytokines, such as IL-17A and IFN-c, in human
polymorphic cells. Results obtained in vivo confirmed that IL-17A
was induced in the lungs of mice treated with high concentrations
of S100B. Thus, proinflammatory cytokines, known to contribute
to progression and severity of A. fumigatus infection [38], are
activated upon sustained RAGE engagement in vivo. Indeed,
increased fungal growth and lung inflammation were observed in
infected mice treated with high concentrations of S100B [15]. Of
interest, the ability of A. fumigatus conidia to up-regulate RAGE
expression suggests that the fungus itself may be able to induce
sustained hyperactivation of the receptor promoting a feed-
forward loop towards uncontrolled inflammation that may
ultimately favor disease progression.
The +427C/T polymorphism in S100B has recently been
described to underlie increased serum levels of the protein [21].
Given the location of the polymorphism in the 39-untranslated
region of S100B, in silico prediction revealed changes in binding
sites for the miR-593 and miR3675-3p in the vicinity of the S100B
polymorphism. Although the functional role of the latter has not
yet been defined, miR-593 has been demonstrated to decrease
luciferase activity by degrading the mRNA of the reporter gene
[39]. Accordingly, we found enhanced expression and secretion of
S100B by polymorphic PBMCs in which miR-593 binding is lost.
Importantly, high concentrations of this danger molecule were
found in BAL samples from HSCT recipients with IA receiving
grafts from polymorphic, but not wild-type, donors. This finding,
together with the lack of genetic association of the patient
polymorphism with IA, indicates that the functional consequence
of this polymorphism is contingent upon the hematopoietic
compartment, likely myeloid dendritic cells [40], of the donor.
Soluble RAGE (sRAGE), an isoform of RAGE lacking
transmembrane and cytosolic domains, acts as a decoy receptor
for RAGE ligands in the extracellular compartment, and is
believed to afford protection against inflammation and cell injury
[41]. Reportedly, sRAGE levels are reduced in patients with
inflammatory diseases as compared with healthy subjects [42].
However, the fact that no significant differences in the levels of
sRAGE were observed among patients with distinct patient/donor
RAGE genotypes suggests that neither the increased expression of
RAGE nor of S100B was associated with decreased production
and functional activity of sRAGE.
In summary, our findings highlight a previously undisclosed role
for genetic variants in the S100B/RAGE axis as risk factors to IA
in the HSCT setting. Thus, screening of patients for RAGE and
S100B status before HSCT might be useful to a more risk-adapted,
prophylactic approach and, whenever possible, for adequate
donor selection. The significance of RAGE and S100B variants
should nonetheless be interpreted with caution. Although
associations were corrected for known important clinical factors,
there are variables in transplanted patients that are difficult to
Figure 2. Functional consequences of RAGE -374T/A polymorphism. Analysis of RAGE expression in PBMCs from wild-type (WTRAGE, TT
genotype) or mutant homozygous (SNPRAGE, AA genotype) individuals (A) untreated or (B) stimulated with A. fumigatus conidia (Af), S100B and
HMGB1. In (A), a representative Western blot of RAGE in untreated WTRAGE and SNPRAGE PBMCs is shown. Tub, tubulin. (C) Cytokine gene expression in
human PBMCs isolated from WTRAGE or SNPRAGE individuals. Data are shown as mRNA relative expression using untreated WTRAGE cells as reference
(for every assay, shown is the mean6SD of data obtained for 10 individuals of each genotype; *P#0.05 and **P#0.01 by unpaired t-test). Cells from
the same individuals were used across conditions in each assay.
doi:10.1371/journal.pone.0027962.g002
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account for. The type of transplant (T-cell depleted) and the size of
the cohort may limit the clinical translation of the findings. Despite
the fact that validation studies are still currently underway in
additional patient cohorts and the mechanisms underlying the
increased susceptibility to infection cannot be definitely pinpoint-
ed, a genetically-determined hyperfunction of the S100B/RAGE
axis is probably involved. Moreover, within the cross-talk between
RAGE and TLRs in inflammatory and immune responses with
[15] and without infection [43–44], it is conceivable that the role
of DAMP signaling may go beyond the infection control to include
important inflammatory post-transplant events. Furthermore, the
finding that miRNAs could target DAMP genes in infection is of
potential interest and warrants further investigation. Because
expression of miRNAs is unbalanced in various pathological states
and, importantly, they are abundantly present and easy detectable
in body fluids [45], it is conceivable that miRNAs may serve as
novel biomarkers for fungal diseases in HSCT.
Supporting Information
Figure S1 Polymorphisms in the S100B/RAGE axis and
risk of CMV disease in HSCT recipients. (A) Cumulative
incidence of CMV disease according to RAGE-374T/A genotype
(WTRAGE, TT; SNPRAGE, TA+AA). (B) Cumulative incidence of CMV
disease according to S100B +427C/T genotype (WTS100B, CC;
SNPS100B, CT+TT). From left to right, patients (R) and donors (D).
(TIF)
Figure S2 Cytokine gene expression in human PBMCs
isolated from WTRAGE or SNPRAGE individuals. Data are
shown as mRNA relative expression of IL10, IL6 and TNF using
untreated WTRAGE cells as reference (mean6SD of 10 indepen-
dent experiments; *P#0.05 and **P#0.01 by unpaired t-test).
(TIF)
Figure 3. Functional consequences of S100B +427C/T polymorphism. (A) In silico search for miRNAs targeting S100B in the vicinity of the
polymorphism. Putative binding sites for miR-593 in WTS100B and miR3675-3p in SNPS100B sequences are shown. Underlined sequences indicate
‘‘seed’’ sequences. (B) Analysis of S100B mRNA expression or (C) protein secretion in WTS100B (wild-type, CC genotype) or SNPS100B (CT genotype)
PBMCs either left untreated or stimulated with A. fumigatus conidia (Af) and Zymosan (Zym). Data are shown as mRNA relative expression using
untreated WTS100B cells as reference or as absolute quantity of S100B in culture supernatants (for every assay, shown is the mean6SD of data
obtained for 10 individuals of each genotype; **P#0.01 by unpaired t-test). Cells from the same individuals were used across conditions in each assay.
doi:10.1371/journal.pone.0027962.g003
Figure 4. S100B concentrations in BAL samples from patients
with proven/probable IA (n=26) that received graft from wild-
type (WTS100B , n = 13) or polymorphic (SNPS100B , n = 13) donors.
Median S100B levels: 203 pg/mL and 3218 pg/mL for patients with IA
receiving graft from WTS100B or SNPS100B donors, respectively (P=0.016,
by Mann-Whitney U test).
doi:10.1371/journal.pone.0027962.g004
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Figure S3 Cytokine gene expression in the lungs of A.
fumigatus-infected mice. C57BL/6 and Rage-/- mice were
infected with A. fumigatus conidia intranasally and were either left
untreated (-) or treated with S100B and HMGB1. mRNA levels of
Il17a, Ifng, Il10 and Il4 were assessed at 3 days postinfection
(n = 628 mice from each genotype, 3 independent experiments
performed in duplicate; **P#0.01 by ANOVA).
(TIF)
Figure S4 Soluble RAGE concentrations in BAL samples
from patients with proven/probable IA according to
donor and patient genotype (n=5 for each category).
(TIF)
Table S1 Primers used in this study.
(DOC)
Table S2 Genotype distributions of RAGE and S100B
polymorphisms in hematological patients undergoing
HSCT and healthy controls.
(DOC)
Table S3 Genotype distribution of RAGE and S100B
polymorphisms according to antifungal prophylaxis.
(DOC)
Methods S1 Fungal strains, infections, and treatments.
Female C57BL/6, 8 to 10 weeks old mice, were purchased from
Charles River Laboratories (Calco, Italy). Homozygous Rage-/-
mice were a kind gift from Angelika Bierhaus (Heidelberg,
Germany). Mice were bred under specific pathogen-free condi-
tions at the Animal Facility of Perugia University, Perugia, Italy
and experiments were performed according to the Italian
Approved Animal Welfare Assurance A–3143–01 and the
legislative decree 157/2008-B regarding the animal license
obtained by the Italian Ministry of Health (2008–2011). All efforts
were made to minimize suffering. Viable conidia (. 95%) from
the A. fumigatus Af293 strain were obtained by growth on
Sabouraud dextrose agar (Difco Laboratories, Detroit) supple-
mented with chloramphenicol for 4 days at room temperature.
Fungi were suspended in endotoxin-free (Detoxi-gel; Pierce
Chemical, Rockford, IL, USA) solutions (,1.0 EU/mL, as
determined by the Limulus amebocyte lysate method). For
infection, mice were anesthetized by intraperitoneal injection
(i.p.) of 2.5% avertin (Sigma-Aldrich Co) before instillation of a
suspension of 26107 conidia/20 mL saline intranasally. Mice were
treated daily i.p. for 3 consecutive days starting the day of infection
with 50 and 500 ng/Kg of purified S100B, 5 and 50 mg/Kg
HMGB1 (Sigma-Aldrich Co), at the end of which total RNA was
extracted from the lungs. ELISA for sRAGE. ELISA was
performed using the human RAGE Quantikine assay (R&D
Systems, MN, USA) according to the manufacturer’s instructions.
This assay measures the total pool of sRAGE which is generated
either by splicing or cleavage (e.g. sRAGE or esRAGE).
(DOC)
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